Clinical Diagnosis

Poll: Do you believe biosimilars have the same efficacy as branded medications?

Weigh in on this month's survey question. The poll will be open until December 16, 2022.

Azura Ophthalmics reveals positive results from phase 2b clinical trial of AZR-MD-001 for meibomian gland dysfunction

AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of MGD.

The emerging biosimilars: highlights on use in retinal diseases

The regulatory process is building confidence that the product is good and can be used safely.

Boarding Orbis Flying Eye Hospital: Not your typical flight experience

November 16, 2022

When it is not on a mission, the Orbis Flying Eye Hospital MD-10 aircraft often is situated at an airport where the fully accredited teaching facility is put to use as a mobile simulation center to train ophthalmologists from around the world in some of the latest sight-saving techniques.

AI-empowered diagnostic retina scans can help prevent heart and kidney diseases

November 10, 2022

Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.

EP. 5: EyeCon 2022: Last chance to earn those end-of-year CME credits

November 10, 2022

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.